cpx-351 and gemtuzumab ozogamicin in r/r aml and mds
Published 1 year ago • 162 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
2:11
cpx-351 plus venetoclax in patients with newly-diagnosed high-risk aml
-
3:21
safety run-in of a phase ii trial of cpx-351 plus pomalidomide in aml with mds-related changes
-
0:52
a real-world study of the optimal duration of cpx-351 treatment in patients with aml
-
1:12
cpx-351 with venetoclax in r/r aml: results of a phase ib study
-
1:30
the current role of cpx-351 in aml and clinical trials evaluating this agent
-
1:55
long-term real-world experience of cpx-351 in patients with t-aml and mrc-aml
-
15:27
naomi wu's nukit 222nm sterilising excimer light
-
30:14
hematology analyzer installation and operation video
-
10:42
gene set analysis of gwas with magma in omicsbox
-
1:30
evaluating the optimal duration of cpx-351 treatment & best timing for allosct consolidation in aml
-
1:08
the real-world safety and efficacy of cpx-351 in patients with aml
-
1:40
the role of cpx-351 in the aml treatment landscape & insights into the amlsg 30-18 trial
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
2:03
an update on the phase ii/iii imerge trial of imetelstat in lr-mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
0:36
the promise of cpx-351 in secondary aml
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
2:20
pevonedistat, azacitidine and venetoclax triplet therapy for aml, mds and cmml
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials